Current Report Filing (8-k)
November 29 2016 - 8:21AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 26, 2016
Lotus Bio-Technology Development Corp.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
Nevada
|
000-54745
|
TBA
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
|
|
|
|
28202 N.58
th
Street, Cave Creek, NV
|
85331
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
|
|
Registrant’s telephone number, including area code: 480-275-2294
|
|
|
|
|
|
__________________Starflick.com_________________________________
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
|
|
|
|
[ ]
|
Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
1
Item 1.02 Termination of a Material Definitive Agreement.
On November 25, 2016, Lotus Bio-Technologies Development Corp. (the "Company") sent a notice to CBD SOCO. (CBD) terminating, effective immediately, the Material Definitive Agreement dated October 24, 2016, between the Company and CBD regarding the proposed asset purchase of all assets, trade secrets, intellectual property, and proprietary information of CBD.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Lotus Bio-Technology Development Corp.
/s/ Michael Palethorpe
Michael Palethorpe
Chief Executive Officer
Date: November 29, 2016
3
Lotus Bio Technology Dev... (CE) (USOTC:LBTD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lotus Bio Technology Dev... (CE) (USOTC:LBTD)
Historical Stock Chart
From Apr 2023 to Apr 2024
